Hutchmed Sustainability Profile
Hutchmed, officially known as Hutchison China MediTech Limited, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, Hutchmed has rapidly established itself as a leader in the oncology and immunology sectors, focusing on the discovery, development, and commercialisation of innovative therapies. With a strong operational presence in China and the United States, Hutchmed has achieved significant milestones, including the successful launch of its flagship products, which are designed to address unmet medical needs in cancer treatment. The company’s unique approach combines cutting-edge research with a deep understanding of local markets, positioning it favourably within the competitive biopharmaceutical landscape. Hutchmed's commitment to advancing healthcare solutions has garnered recognition, making it a notable player in the global biopharmaceutical industry.
DitchCarbon Score
How does Hutchmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hutchmed's score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hutchmed's reported carbon emissions
In 2024, Hutchmed reported total carbon emissions of approximately 107,851,000 kg CO2e, with emissions distributed across all three scopes: Scope 1 emissions were about 3,083,000 kg CO2e, Scope 2 emissions totalled approximately 13,234,000 kg CO2e, and Scope 3 emissions reached around 107,851,000 kg CO2e. The company has set ambitious reduction targets, aiming to decrease carbon emissions intensity by 30% for Scope 1 and by 10% for Scope 2, both from a 2020 baseline, by 2025. Additionally, Hutchmed plans to reduce emissions intensity from business air travel by 10% from a 2019 baseline by 2025. Hutchmed is committed to achieving net-zero emissions by 2050, focusing on sustainable pharmaceutical production and impactful partnerships. This long-term goal reflects the company's dedication to addressing climate change and reducing its environmental footprint. The emissions data is sourced from Hutchmed (China) Limited, with no cascaded data from a parent organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 672,000 | 0,000,000 | 000,000 | 00,000,000 | 000,000,000 |
How Carbon Intensive is Hutchmed's Industry?
How Carbon Intensive is Hutchmed's Location?
Hutchmed's Scope 3 Categories Breakdown
Hutchmed's Scope 3 emissions, which increased by 50% last year and increased significantly since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Hutchmed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hutchmed has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
